pLenti CMV SNAT2-eGFP 3NQ
(Plasmid
#237227)
-
PurposeLentiviral destination vector expressing sgRNA-resistant SNAT2 (SLC38A2) cDNA containing C-terminal eGFP. SNAT2 sequence contains mutations to inhibit N-linked glycosylation.
-
Depositing Lab
-
Sequence Information
Ordering
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 237227 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $94 | |
Backbone
-
Vector backbonepLenti CMV Blast DEST (706-1)
-
Backbone manufacturerEric Campeau, Paul Kaufman (Addgene plasmid #17451)
- Backbone size w/o insert (bp) 9331
- Total vector size (bp) 9966
-
Vector typeMammalian Expression, Lentiviral
-
Selectable markersBlasticidin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameSLC38A2
-
SpeciesH. sapiens (human)
-
Insert Size (bp)2274
-
MutationSilent mutations to prevent targeting by sgRNA sequence: TAATCTGAGCAATGCGATTG; 3 asparagine residues mutated to glutamine to inhibit N-linked glycosylation: N254Q, N258Q, N274Q
-
Entrez GeneSLC38A2 (a.k.a. ATA2, PRO1068, SAT2, SNAT2)
- Promoter CMV
-
Tag
/ Fusion Protein
- eGFP
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer CMV Forward
- (Common Sequencing Primers)
Resource Information
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pLenti CMV SNAT2-eGFP 3NQ was a gift from Seth Parker (Addgene plasmid # 237227 ; http://n2t.net/addgene:237227 ; RRID:Addgene_237227) -
For your References section:
N-linked glycosylation regulates SNAT2 trafficking and stability in pancreatic ductal adenocarcinoma cells. Koe JC, Pashaoskooie K, Johal D, Zhong YC, Wu C, Parker SJ. Am J Physiol Cell Physiol. 2026 Jun 29. doi: 10.1152/ajpcell.00060.2026. 10.1152/ajpcell.00060.2026 PubMed 42370970